Investment analysts at HC Wainwright assumed coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) in a note issued to investors on Wednesday, MarketBeat reports. The brokerage set a “neutral” rating and a $8.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 4.17% from the stock’s previous close.
Kyverna Therapeutics Stock Down 4.6 %
Kyverna Therapeutics stock opened at $7.68 on Wednesday. The stock’s 50 day moving average is $12.16. Kyverna Therapeutics has a twelve month low of $6.75 and a twelve month high of $35.06.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.28). During the same period last year, the firm posted ($12.10) earnings per share. As a group, research analysts forecast that Kyverna Therapeutics will post -3.6 EPS for the current year.
Institutional Inflows and Outflows
Kyverna Therapeutics Company Profile
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Read More
- Five stocks we like better than Kyverna Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What is the Hang Seng index?
- AbbVie Stock: A Perfect Dip for Investors to Buy
- The Role Economic Reports Play in a Successful Investment Strategy
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.